文献速递冠心病血脂与心血管预防

全基因组测序揭示早发心肌梗死的单基因与多基因贡献

Whole-Genome Sequencing to Characterize Monogenic and Polygenic Contributions in Patients Hospitalized With Early-Onset Myocardial Infarction.
PubMed 文献 · Circulation · 2019-01-01

该研究对2081例早发心肌梗死患者和3761例对照进行全基因组测序,发现家族性高胆固醇血症突变检出率1.7%,与心肌梗死风险增加3.8倍相关;高多基因评分检出率17.3%,与风险增加3.7倍相关,且高多基因评分患病率是前者的10倍。

要点

  • 早发心梗患者中高多基因评分患病率17.3%,远高于家族性高胆固醇血症突变的1.7%。
  • 家族性高胆固醇血症突变与心梗风险增加3.8倍相关,高多基因评分与风险增加3.7倍相关。
  • 高多基因评分在白色人种中关联最强,但所有种族均显示风险增加。

核心结论

  • 家族性高胆固醇血症突变和高多基因评分均与早发心肌梗死风险增加超过3倍相关。
  • 高多基因评分在早发心肌梗死患者中的患病率是家族性高胆固醇血症突变的10倍。

研究设计与样本

  • 对2081例美国住院的早发心肌梗死患者(年龄≤55岁,女性与男性入组比例2:1)进行深度覆盖全基因组测序。
  • 与3761例人群对照进行比较。
  • 高多基因评分定义为对照组分布的前5%。

主要发现

  • 早发心肌梗死患者平均年龄48岁,66%为女性。
  • 36例(1.7%)携带家族性高胆固醇血症突变,与心肌梗死风险增加3.8倍相关(95% CI, 2.1-6.8; P<0.001)。
  • 359例(17.3%)携带高多基因评分,与心肌梗死风险增加3.7倍相关(95% CI, 3.1-4.6; P<0.001)。
  • 估计未治疗低密度脂蛋白胆固醇平均水平:家族性高胆固醇血症突变者为206 mg/dL,高多基因评分者为132 mg/dL,其余人群为122 mg/dL。
  • 高多基因评分在所有种族中均与风险增加相关,但在白色人种中关联最强(异质性P=0.008)。

临床怎么用

  • 对早发心肌梗死患者应考虑评估家族性高胆固醇血症突变和高多基因评分,以识别高风险个体。
  • 高多基因评分在早发心梗患者中更常见,可能作为风险分层工具。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The relative prevalence and clinical importance of monogenic mutations related to familial hypercholesterolemia and of high polygenic score (cumulative impact of many common variants) pathways for early-onset myocardial infarction remain uncertain. Whole-genome sequencing enables simultaneous ascertainment of both monogenic mutations and polygenic score for each individual. METHODS: We performed deep-coverage whole-genome sequencing of 2081 patients from 4 racial subgroups hospitalized in the United States with early-onset myocardial infarction (age ≤55 years) recruited with a 2:1 female-to-male enrollment design. We compared these genomes with those of 3761 population-based control subjects. We first identified individuals with a rare, monogenic mutation related to familial hypercholesterolemia. Second, we calculated a recently developed polygenic score of 6.6 million common DNA variants to quantify the cumulative susceptibility conferred by common variants. We defined high polygenic score as the top 5% of the control distribution because this cutoff has previously been shown to confer similar risk to that of familial hypercholesterolemia mutations. RESULTS: The mean age of the 2081 patients presenting with early-onset myocardial infarction was 48 years, and 66% were female. A familial hypercholesterolemia mutation was present in 36 of these patients (1.7%) and was associated with a 3.8-fold (95% CI, 2.1-6.8; P<0.001) increased odds of myocardial infarction. Of the patients with early-onset myocardial infarction, 359 (17.3%) carried a high polygenic score, associated with a 3.7-fold (95% CI, 3.1-4.6; P<0.001) increased odds. Mean estimated untreated low-density lipoprotein cholesterol was 206 mg/dL in those with a familial hypercholesterolemia mutation, 132 mg/dL in those with high polygenic score, and 122 mg/dL in those in the remainder of the population. Although associated with increased risk in all racial groups, high polygenic score demonstrated the strongest association in white participants ( P for heterogeneity=0.008). CONCLUSIONS: Both familial hypercholesterolemia mutations and high polygenic score are associated with a >3-fold increased odds of early-onset myocardial infarction. However, high polygenic score has a 10-fold higher prevalence among patients presents with early-onset myocardial infarction. CLINICAL TRIAL REGISTRATION: URL: https://www.clinicaltrials.gov . Unique identifier: NCT00597922.

来源:Circulation,查看原文。版权归原作者所有。

引用

  1. Khera AV, Chaffin M, Zekavat SM, et al. Whole-Genome Sequencing to Characterize Monogenic and Polygenic Contributions in Patients Hospitalized With Early-Onset Myocardial Infarction. Circulation. 2019. PMID: 30586733. doi:10.1161/CIRCULATIONAHA.118.035658

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。